Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown...

Full description

Bibliographic Details
Main Authors: Tilman Todenhöfer, Arnulf Stenzl, Lorenz C. Hofbauer, Tilman D. Rachner
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2015/838202